Skip to main content
. 2014 Dec 15;3:740. doi: 10.1186/2193-1801-3-740

Table 1.

Summary statistics of explanatory variables and effect sizes

Variable n %
Total number of test drug-comparator pairs observed 194 100
Endpoint HDRS 19 10
PANSS 12 6
PEF 16 8
Blood pressure 41 21
HbA1c 24 12
CGI-I Depression 33 17
Schizophrenia 25 13
Asthma 24 12
Comparator Placebo 44 23
Active 150 77
Statistical purpose Superiority 32 17
Non-inferiority and equivalence 57 29
Dose response 20 10
Other 85 44
Number of arms 2 142 73
3 28 14
4 22 11
5 2 1
All 194 2.40 (0.729)a
Sample size 194 236 (108)a
Length of trial (weeks) 194 8.54 (4.10)a
Mean number of subjects per site 182 5.14 (3.20)a
Approval year 194 1999b
Dosing schedule Flexible 109 56
Fixed 85 44
Type of endpoint Subjective endpoint (assessment score) 30 15
Subjective endpoint 84 43
(Clinical Global Improvement)
Objective endpoint 80 41
Primary endpoint
Yes 147 76
No 47 24
Comparator with the same mode of action of the test drug
Yes 153 79
No 41 21
Phase2
Yes 36 19
No 158 81
Precedent foreign clinical trial data
Yes 83 43
No 111 57
Companies' domestic development experience with similar drugs
Yes 91 47
No 103 53
Mean age of subjects 193 48.0 (7.63)a
Ratio of female subjects 194 0.47 (0.10)a
Effect size Placebo 44 0.58 (0.52)a
Active 150 0.08 (0.22)a

aMean (SD), bMedian.

Precedent foreign clinical data: a dummy variable that was assigned a value of 1 if foreign clinical trials were included in the clinical data package. Companies’ domestic development experience with similar drugs: a dummy variable that was assigned a value of 1 when a company had gained at least one drug approval for the same therapeutic indication in Japan before the approval of a drug we analyzed.

HDRS: the Hamilton Depression Rating Scale for depression, PNASS: Positive and Negative Syndrome Scale for schizophrenia, PEF: morning Peak Expiratory Flow for asthma, Blood pressure: diastolic pressure for hypertension, HbA1c: hemoglobin A1c for diabetes, CGI-I: Clinical Global Impression of Improvement.